JAK
Los inhibidores de la Janus quinasa (JAK) son compuestos que se dirigen a la vía de señalización JAK-STAT, la cual está involucrada en el crecimiento celular, la respuesta inmunitaria y la angiogénesis. Al inhibir JAK, estos compuestos pueden reducir la señalización que conduce a la formación de nuevos vasos sanguíneos en los tumores, inhibiendo así el crecimiento tumoral. Los inhibidores de JAK son importantes en el tratamiento del cáncer y las enfermedades inflamatorias. En CymitQuimica, ofrecemos una amplia gama de inhibidores de JAK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 245 productos de "JAK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Fórmula:C25H28N6O2Pureza:99.19%Forma y color:SolidPeso molecular:444.532,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Fórmula:C16H13Cl2N3O2Pureza:98.77%Forma y color:SolidPeso molecular:350.2Cerdulatinib
CAS:<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Fórmula:C20H27N7O3SPureza:98.74% - 99.49%Forma y color:SolidPeso molecular:445.54Protosappanin A
CAS:<p>Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.</p>Fórmula:C15H12O5Pureza:99.42% - 99.82%Forma y color:SolidPeso molecular:272.25AMG-47a
CAS:<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Fórmula:C29H28F3N5O2Pureza:98%Forma y color:SolidPeso molecular:535.56Decernotinib
CAS:<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Fórmula:C18H19F3N6OPureza:99.28% - >99.99%Forma y color:SolidPeso molecular:392.38G5-7
CAS:<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Fórmula:C22H19F2NO3Pureza:97.3%Forma y color:SolidPeso molecular:383.39(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Fórmula:C23H24N4OPureza:97.75% - 99.92%Forma y color:SolidPeso molecular:372.46FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Fórmula:C28H32O6Pureza:97% - 97.90%Forma y color:SolidPeso molecular:464.55AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Forma y color:Yellow SolidPeso molecular:294.3GDC-0214
CAS:<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Fórmula:C28H28ClF2N9O3Pureza:99.75%Forma y color:SolidPeso molecular:612.03Baricitinib
CAS:<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Fórmula:C16H17N7O2SPureza:99% - >99.99%Forma y color:SolidPeso molecular:371.42Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Fórmula:C18H22N4O2Pureza:98.67% - 99.4%Forma y color:SolidPeso molecular:326.39Pyridone 6
CAS:<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Fórmula:C18H16FN3OPureza:97.1% - 98.74%Forma y color:SolidPeso molecular:309.34WHI-P97
CAS:<p>WHI-P97 is a rationally designed potent inhibitor of JAK-3.</p>Fórmula:C16H13Br2N3O3Pureza:99.93%Forma y color:SolidPeso molecular:455.1JANEX-1
CAS:<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>Fórmula:C16H15N3O3Pureza:98% - 99.81%Forma y color:SolidPeso molecular:297.31WP1066
CAS:<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Fórmula:C17H14BrN3OPureza:98.92% - 99.73%Forma y color:SolidPeso molecular:356.22Fedratinib hydrochloride hydrate
CAS:<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Fórmula:C27H40Cl2N6O4SPureza:98.96% - 99.87%Forma y color:SolidPeso molecular:615.61AZ960
CAS:<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Fórmula:C18H16F2N6Pureza:96.02% - 98.51%Forma y color:SolidPeso molecular:354.36ZM39923 hydrochloride
CAS:<p>ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.</p>Fórmula:C23H25NO·HClPureza:98.05%Forma y color:SolidPeso molecular:367.91BMS-911543
CAS:<p>BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.</p>Fórmula:C23H28N8OPureza:97.69% - 99.98%Forma y color:SolidPeso molecular:432.52SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Fórmula:C21H18ClFN4O4Pureza:98.99% - 99.77%Forma y color:SolidPeso molecular:444.84FM-381
CAS:<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Fórmula:C24H24N6O2Pureza:98.44%Forma y color:SolidPeso molecular:428.49TG101209
CAS:<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Fórmula:C26H35N7O2SPureza:99% - >99.99%Forma y color:SolidPeso molecular:509.67Deucravacitinib
CAS:Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.Fórmula:C20H19D3N8O3Pureza:98.52% - >99.99%Forma y color:SolidPeso molecular:425.46RO495
CAS:<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Fórmula:C17H14Cl2N6OPureza:97.94%Forma y color:SolidPeso molecular:389.24SC99
CAS:SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.Fórmula:C15H8Cl2FN3OPureza:99.56%Forma y color:SolidPeso molecular:336.15Brevilin A
CAS:<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Fórmula:C20H26O5Pureza:99.97% - >99.99%Forma y color:SolidPeso molecular:346.42Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Fórmula:C20H28ClN7O3SPureza:99.85%Forma y color:SolidPeso molecular:482GS-829845
CAS:<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Fórmula:C17H19N5O2SPureza:99.93%Forma y color:SolidPeso molecular:357.43NVP-BSK805
CAS:<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Fórmula:C27H28F2N6OPureza:98%Forma y color:SolidPeso molecular:490.55Solrikitug
CAS:<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Pureza:95%Forma y color:LiquidZM39923
CAS:<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Fórmula:C23H25NOPureza:98%Forma y color:SolidPeso molecular:331.45(3S,4S)-Tofacitinib
CAS:<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Fórmula:C16H20N6OPureza:98%Forma y color:SolidPeso molecular:312.37SD-1029
CAS:<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>Fórmula:C25H32Br2Cl2N2O3Forma y color:SolidPeso molecular:639.25JAK-IN-11
CAS:<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Fórmula:C23H22FN5O4SPureza:99.75%Forma y color:SolidPeso molecular:483.52JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Forma y color:SolidPeso molecular:515.58JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Fórmula:C19H19ClN2OSForma y color:SolidPeso molecular:358.89Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Forma y color:SolidPeso molecular:362.86TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Fórmula:C21H22N2O2Forma y color:SolidPeso molecular:334.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Fórmula:C19H19N3O4SForma y color:SolidPeso molecular:385.44JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Fórmula:C19H15FN4OPureza:98.27%Forma y color:SolidPeso molecular:334.35TyK2-IN-2
CAS:<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Fórmula:C16H18N6OPureza:98%Forma y color:SolidPeso molecular:310.35JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Fórmula:C27H28F2N6O3Forma y color:SolidPeso molecular:522.55JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Fórmula:C19H19N5O4SForma y color:SolidPeso molecular:413.45Tyk2-IN-5
CAS:<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Fórmula:C21H19FN8O2Pureza:98%Forma y color:SolidPeso molecular:434.43EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Fórmula:C14H24O2Forma y color:SolidPeso molecular:224.34Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Fórmula:C18H15D3N6O3SPureza:98%Forma y color:SolidPeso molecular:401.46MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Fórmula:C21H18N2O3Pureza:98%Forma y color:SolidPeso molecular:346.381,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Fórmula:C6H6Br6Pureza:98%Forma y color:SolidPeso molecular:557.54OICR-0547
CAS:<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Fórmula:C28H29F3N4O4Pureza:98%Forma y color:SolidPeso molecular:542.55INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Fórmula:C19H11Cl2N5Forma y color:SolidPeso molecular:380.23JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Fórmula:C17H23N5O4SForma y color:SolidPeso molecular:393.46TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Fórmula:C22H25F2N5O2Forma y color:SolidPeso molecular:429.46CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Forma y color:SolidPeso molecular:303.36GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Fórmula:C21H18ClF2N7O3Forma y color:SolidPeso molecular:489.86Peficitinib hydrobromide
CAS:<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Fórmula:C18H23BrN4O2Forma y color:SolidPeso molecular:407.312Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Fórmula:C23H22F5N7OForma y color:SolidPeso molecular:507.469(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Fórmula:C15H19N5OForma y color:SolidPeso molecular:285.34TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Fórmula:C18H17N5O3SForma y color:SolidPeso molecular:383.42Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Fórmula:C28H28ClN5O4SForma y color:SolidPeso molecular:566.07PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Fórmula:C18H26N6OForma y color:SolidPeso molecular:342.44SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Fórmula:C24H26N8O3Forma y color:SolidPeso molecular:474.52JAK3-IN-1
CAS:<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Fórmula:C26H30ClN7O2Forma y color:SolidPeso molecular:508.02JAK-IN-10
CAS:<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Fórmula:C20H18FN5O3SPureza:99.53%Forma y color:SolidPeso molecular:427.45JAK-IN-28
CAS:<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>Fórmula:C20H18ClN7OPureza:98%Forma y color:SolidPeso molecular:407.86JAK-IN-30
CAS:<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>Fórmula:C19H26N8SPureza:98%Forma y color:SolidPeso molecular:398.53JAK1-IN-4
CAS:<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Fórmula:C26H32FN9O2Pureza:98%Forma y color:SolidPeso molecular:521.59JAK3/BTK-IN-2
CAS:<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Fórmula:C25H32N8O2Pureza:99.64% - 99.87%Forma y color:SolidPeso molecular:476.57Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Fórmula:C22H28N6O2Pureza:99.72%Forma y color:SolidPeso molecular:408.5JAK3i
CAS:<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Fórmula:C18H15FN4O3Pureza:98.61% - 99.81%Forma y color:SolidPeso molecular:354.34Jaspamycin
CAS:<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Fórmula:C12H12N4O5Forma y color:SolidPeso molecular:292.25JAK3/BTK-IN-1
CAS:<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Fórmula:C25H28N8OPureza:97.89%Forma y color:SolidPeso molecular:456.54Izencitinib
CAS:<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Fórmula:C22H26N8Pureza:99.82%Forma y color:SolidPeso molecular:402.50STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Fórmula:C15H15ClN4O2Pureza:99.01%Forma y color:SolidPeso molecular:318.76JAK1-IN-8
CAS:<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Fórmula:C22H23FN4O3SPureza:98.4%Forma y color:SolidPeso molecular:442.51JAK-STAT-IN-1
CAS:<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Fórmula:C21H21N5O2Pureza:99.59%Forma y color:SolidPeso molecular:375.42Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Fórmula:C29H32Cl2N2O5SPureza:99.51% - 99.83%Forma y color:SoildPeso molecular:591.55JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Fórmula:C19H17N5O4Pureza:98%Forma y color:SolidPeso molecular:379.37Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Fórmula:C30H37N7O2Forma y color:SolidPeso molecular:527.66Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Fórmula:C21H33F3N6O11Pureza:98%Forma y color:SolidPeso molecular:602.521JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Fórmula:C33H38F2N6O8Forma y color:SolidPeso molecular:684.69TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Fórmula:C27H25F3N4O4Pureza:99.39% - ≥98%Forma y color:SolidPeso molecular:526.51Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Fórmula:C18H21N5O3Pureza:99.85%Forma y color:SolidPeso molecular:355.39JAK kinase-IN-1
CAS:<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Fórmula:C17H19F2N7OSPureza:98%Forma y color:SolidPeso molecular:407.44JAK-IN-5
CAS:<p>JAK-IN-5 is a JAK inhibitor.</p>Fórmula:C27H31FN6OPureza:98.1% - 99.37%Forma y color:SolidPeso molecular:474.57JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Fórmula:C20H24N6O2Pureza:98%Forma y color:SolidPeso molecular:380.44Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Fórmula:C22H20N6O3Forma y color:SolidPeso molecular:416.43FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Fórmula:C25H26N6O2Pureza:98%Forma y color:SolidPeso molecular:442.523JAK2-IN-4
CAS:<p>JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.</p>Fórmula:C23H27N5O4SPureza:98%Forma y color:SolidPeso molecular:469.56TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Fórmula:C17H11ClF2N4O2Forma y color:SolidPeso molecular:376.74Brepocitinib
CAS:<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Fórmula:C18H21F2N7OPureza:99.82%Forma y color:SolidPeso molecular:389.4ABBV-712
CAS:<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Fórmula:C24H28N4O5Pureza:98%Forma y color:SolidPeso molecular:452.5Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Fórmula:C20H17N9Pureza:98%Forma y color:SolidPeso molecular:383.41JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Fórmula:C20H25N5O2Forma y color:SolidPeso molecular:367.44JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Fórmula:C18H21N4Na2O6PPureza:98%Forma y color:SolidPeso molecular:466.341Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Fórmula:C26H29ClN8OForma y color:SolidPeso molecular:505.01Ginsenoside Rk1
CAS:<p>Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.</p>Fórmula:C42H70O12Pureza:98.46% - 99.13%Forma y color:SolidPeso molecular:767JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Fórmula:C22H24N6O3Pureza:98%Forma y color:SolidPeso molecular:420.46QL-1200186
CAS:<p>QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following</p>Fórmula:C26H27N7O3Pureza:98%Forma y color:SolidPeso molecular:485.54
